The Clinton HIV/AIDS Initiative (CHAI) and UNITAID have announced agreements with drug manufacturers to significantly reduce the price of key HIV/AIDS medicines. Among other things, the new agreements will further lower the cost of the most affordable generic second-line ARV regimen by 17 per cent compared to prices announced by the two groups last year, and by 18 per cent and 39 per cent compared to average market prices in low- and middle-income countries.